The HBOT and Telomere Study: What the 2020 Aging Paper Actually Reported
A 2020 trial reported longer telomeres and fewer senescent cells after 60 HBOT sessions. The findings are striking but hypothesis-generating, not proof of slower aging.
What the study set out to measure
In 2020, researchers led by Shai Efrati and Amir Hadanny at Israel's Sagol Center published a paper in the peer-reviewed journal Aging that drew wide attention. The team enrolled 35 healthy, independent older adults and gave each of them 60 daily HBOT sessions over roughly 90 days. The goal was narrow and specific: to see whether the therapy changed two cellular markers commonly linked to biological aging, namely telomere length and the fraction of senescent cells in the blood.
Telomeres are protective caps on the ends of chromosomes that tend to shorten as cells divide and age. Senescent cells are older cells that stop dividing but linger and can drive inflammation. Both are studied as markers of aging, though neither is a direct measure of how long or how well a person will actually live.
The headline numbers
The reported results were eye-catching. According to the paper, telomere length in isolated immune cells increased by up to roughly 38 percent, and the share of senescent cells fell by up to about 37 percent, with the largest drop seen in a subset of senescent T-helper cells. The authors described the direction of change as comparable to reversing years of the usual age-related trend in these particular markers.
Why the results are hypothesis-generating
Those figures deserve context. The study was small, involved no separate control group, since each participant was compared against their own baseline, and it measured blood-cell markers rather than any clinical outcome such as disease, physical function or lifespan. A change in a marker does not automatically translate into a health benefit, and biological-age markers can shift for many reasons. The researchers themselves framed the work as a prospective trial that opens a question rather than one that settles it.
It is also worth noting how the findings have travelled. The same Israeli group has published a broad body of HBOT research, and the telomere results have since been quoted heavily in commercial anti-aging marketing, often stripped of the caveats the authors attached. A single small trial, however carefully run, is a first data point rather than a foundation, and the leap from a laboratory blood measurement to a promise of youthful rejuvenation is exactly the kind of overreach the study itself does not support.
What it does not tell us
For readers researching the therapy, the practical distinction matters more than the headlines. There is no evidence here that any particular device slows aging; the study used a specific clinical protocol, and browsing options to buy a hyperbaric chamber (buying guide) will not tell you whether a wellness package recreates the exact conditions used in the trial. Independent replication in larger, controlled studies with real health endpoints has not yet confirmed these findings.
The telomere paper is a genuine and interesting piece of research worth knowing about, but it is a starting point, not a promise of a longer life. Anyone considering HBOT for aging-related reasons should read the claims skeptically and discuss them with a qualified physician who can weigh thin evidence against the cost, time and risks involved.